FOLH1 and posterior cortical atrophy: Our study demonstrates that integrating imaging biomarkers derived from 68Ga-PSMA-11 PET/CT, such as intraprostatic SUVmax and established clinical risk scores, significantly improves the prediction of early progression of PCa after primary therapy.